151. Polyunsaturated Fatty Acid Deuteration against Neurodegeneration.
- Author
-
Shchepinov, Mikhail S.
- Subjects
- *
UNSATURATED fatty acids , *ABSTRACTION reactions , *DEUTERATION , *ANIMAL disease models , *MEMBRANE lipids , *RETINAL diseases - Abstract
Oxidative stress is a common feature of genetic and idiopathic neurological diseases that thus far have been intractable to drug therapy. Polyunsaturated fatty acids (PUFAs) form cellular, mitochondrial, retinal, and other membranes highly important in neuronal function. However, PUFAs are susceptible to the noxious lipid peroxidation (LPO) chain reaction, which is a common feature of various neurological and age-related pathologies, making this pathway an attractive target for therapeutic intervention. Regioselective deuteration that reinforces oxidation-prone, bis-allylic sites of PUFAs is a novel, nonantioxidant treatment modality that dramatically reduces LPO, potentially mitigating numerous diseases through preservation of membrane properties and amelioration of oxidative stress. Animal disease models and several ongoing human clinical trials highlight the potential of the deuterated-PUFA (D-PUFA) drug candidates currently in development. LPO of PUFAs is the worst type of oxidative damage because it is not stoichiometric but accretes exponentially, through its autocatalytic, chain reaction format. The slowest, rate-limiting step of the LPO process is a hydrogen atom abstraction off a bis-allylic (between double bonds) site. LPO is detrimental to lipid membranes, and is a common denominator of numerous neurological, mitochondrial and retinal diseases. Antioxidants cannot stop the LPO for several fundamental reasons. PUFAs are essential nutrients and have to be supplied with diet. Supplementing PUFAs deuterated at specific sites (D-PUFA drugs) to slow down LPO is a novel promising treatment modality for various neurological, mitochondrial and retinal diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF